Healthcare
Live Price
Offline$25.77
+0.00% today
1Y Change
-5.01%
Window
Jun 26, 2025 → Jun 18, 2026
Coverage: 251 bars · Jun 26, 2025 → Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Kissei Pharmaceutical Co., Ltd. (KSPHF) is a Healthcare stock with a market cap of $179.08B and listed on OTC. The stock last traded around $25.77 and down 5.0% across the available one-year price window (Jun 26, 2025 → Jun 18, 2026). Baseline metrics include revenue growth of +16.9%, EPS growth of +11.2%, a dividend yield of 3.7%. What stands out right now is revenue +16.9%, EPS +11.2%, free cash flow +142.5% with operating margin -2.3% and ROIC -0.7%. The dividend matters to the case here, with a current yield around 3.7%. Valuation is more restrained than many high-expectation growth names at P/E 12.7 and price/sales 1.9. Overall, the current profile looks closer to a income-oriented value setup than a generic broad-market placeholder. Stock Foundry combines KSPHF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Edge
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
KSPHF
—
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
KSPHF Max Drawdown
-19.22%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for KSPHF and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$69.0B
+5.6% YoY
FY Net Income
$5.3B
-59.1% YoY
Free Cash Flow
-$116.3M
-238.0% YoY
Revenue Growth
+16.9%
EPS Growth
+11.2%
Gross Margin
48.2%
Net Margin
14.8%
Income statement
JPY
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 88.3B | 75.6B | 67.5B | 65.4B | 69.0B |
| Gross Profit | 44.1B | 37.3B | 224M | 238M | 280M |
| Operating Income | 5.8B | 4.0B | -1.1B | -1.4B | 1.5B |
| EBITDA | 20.2B | 18.7B | 3.0B | 2.3B | 4.7B |
| Net Income | 12.0B | 11.2B | 10.5B | 12.9B | 5.3B |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
JPY
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 25.2B | 22.9B | 368M | 247M | 393M |
| Total Assets | 244.1B | 260.9B | 1.7B | 2.0B | 2.4B |
| Total Liabilities | 33.9B | 39.8B | 199M | 297M | 443M |
| Shareholder Equity | 209.0B | 220.0B | 193.9B | 201.4B | 219.3B |
| Total Debt | 1.3B | 1.3B | 1.5B | 1.6B | 1.7B |
| Net Debt | -23.9B | -21.6B | -353M | -230M | -373M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
23M
-282.7% YoY
Capital Expenditures
93M
-98.5% YoY
Free Cash Flow
116M
-238.0% YoY
Key ratios
Gross Margin
48.2%
Operating Margin
-2.3%
Net Margin
14.8%
ROE
6.7%
Debt / Equity
0.01x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.